openPR Logo
Press release

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Analysis, Trends, Growth, Research And Forecast 2033

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

Year End Offer By The Business Research Company - Get 33% Discount On Opportunities And Strategies Reports And 25% Discount On Global Market Reports.

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033.

The Business Research Company's Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2023 identifies the increasing number of people with diabetes as the major driver for the exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market's growth in the forecast period. Diabetes refers to a chronic metabolic disorder characterized by high blood sugar levels (hyperglycemia) over a prolonged period. This condition results from the body's inability to produce enough insulin or effectively use the insulin it produces. EPI therapy, which involves pancreatic enzyme replacement therapy (PERT), can help improve nutrient absorption in people with diabetes and EPI. It can also help improve glycemic control in people with diabetes.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has grown strongly in recent years. It will grow from $5.24 billion in 2023 to $5.69 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.67 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.

Download Free Sample Of Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report - https://www.thebusinessresearchcompany.com/sample_request?id=12992&type=smp

Major competitors in the exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

A key trend in the exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market includes technological advancement. Major companies operating in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are focused on innovating new studies and solutions, such as PACT-CP to sustain their position in the market. For instance, in June 2021, Aimmune Therapeutic, a US-based biopharmaceutical company, launched PACT-CP, a patient-centric chronic pancreatitis registry study, to better understand the unmet needs and therapeutic burden on patients with EPI due to chronic pancreatitis (CP). It is the first real-world registry study for patients with chronic pancreatitis. The study, which will follow about 400 patients at 20 gastroenterology facilities across the United States, was created with the help of patients and expert consultants. The PACT-CP Registry study is a prospective, non-interventional research study for patients receiving gastroenterology treatment diagnosed with EPI due to chronic pancreatitis.

Read More On The Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report Here:
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

The exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market is segmented -
• By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

• By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

• By Drug Type: Generic, Branded

• By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

• By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

• By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market.

The Business Research Company's "Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report 2023" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.

Explore Buying Options For The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992

The Table Of Content For The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Include:
1. Executive Summary
2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Characteristics
3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends And Strategies
4. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market - Macro Economic Scenario
5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size and Growth
……
32. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Benchmarking
33. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market
35. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Future Outlook and Potential Analysis
36. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Analysis, Trends, Growth, Research And Forecast 2033 here

News-ID: 3327325 • Views:

More Releases from The Business research company

Segment Evaluation and Major Growth Areas in the Personalized Testing and Supplements Market
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future. Market Valuation and Expansion Forecast for Personalized Testing
Top Players and Market Competition in the Skin Microbiome Industry
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry. Projected Expansion in the Skin
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market Landscape
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory. Steady Growth Expected in Upadacitinib Market Size Through 2029 The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Market
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field. Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics

All 5 Releases


More Releases for EPI

Emerging Trends to Reshape the Silicon EPI Wafer Market: Next-Generation Silicon …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Silicon EPI Wafer Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size of the silicon epi wafer has experienced consistent expansion in the previous years, seeing a projected rise from a value of $1.8 billion in 2024 to $1.89 billion in 2025. This
Consumer Electronics Adoption Fuels The Silicon Epi Wafer Market: Core Growth En …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations. What Will the Silicon EPI Wafer Industry Market Size Be by 2025? Over recent years, the market size for silicon EPI wafers has seen considerable growth. Predictions indicate an increase from $1.8 billion in 2024 to $1.92 billion in 2025, representing a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this historical
Evolving Market Trends In The Silicon EPI Wafer Industry: Next-Generation Silico …
The Silicon EPI Wafer Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Silicon EPI Wafer Market Size During the Forecast Period? In recent times, the silicon EPI wafer market has witnessed substantial growth. The market size, which stood at $1.8 billion in
EPI Invests $1 Million USD in the EPI Data Center Futurist Scholarship Program
Singapore (15 June 2023) - EPI, the global leader in data center training, audit & certification, is proud to announce the launch of the EPI Data Center Futurist Scholarship program, accompanied by a significant investment of one (1) million US-Dollar. This transformative initiative aims to provide aspiring professionals with the resources and support they need to acquire the specialized knowledge and skills necessary for success in the dynamic data
Epi Wafer Market to Surpass Valuation of US$ 5.8 Bn by 2030 with Rising Demand f …
The global Epi Wafer market is estimated to attain a valuation of US$ 5.8 billion by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6% during the forecast period, 2021-2031. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease. Download the sample report at: https://www.pharmaproff.com/request-sample/1024 Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI